Left Atrial Appendage Closure Devices Market Size, Share & Trends Analysis Report By Product (Endocardial LAA Devices, Epicardial LAA Devices), By End Use (Hospitals, Ambulatory Surgery Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Left Atrial Appendage Closure Devices Market Size

The global left atrial appendage closure devices market size was valued at USD 2.11 billion in 2025 and is projected to grow from USD 2.55 billion in 2026 to USD 11.51 billion by 2034, registering a CAGR of 20.74% during the forecast period from 2026 to 2034. North America dominated the left atrial appendage closure devices market with a market share of 42.6% in 2025.

Left atrial appendage closure (LAAC) is a procedure to seal off the left atrial appendage (LAA), a small sac in the left atrium, to reduce stroke risk in patients with atrial fibrillation (AF). AF causes chaotic heart contractions, leading to blood pooling and clot formation in the left atrial appendage. Closing or removing the left atrial appendage decreases the risk of stroke by eliminating the primary source of clots. This procedure is especially useful for patients who cannot tolerate or do not respond well to blood-thinning medications.

Factors such as the growing incidence of atrial fibrillation (AF) and increased awareness about stroke prevention are primary factors driving this left atrial appendage closure devices market growth. Market expansion is also supported by advances in device technology, such as better safety profiles and more efficient use of instruments. In addition, the demand for left atrial appendage closure devices is increasing due to expanding reimbursement coverage and the growing elderly population, which is more susceptible to atrial fibrillation.

Product Insights

The market is divided into Endocardial LAA Devices and Epicardial LAA Devices. The endocardial LAA devices segment dominates the global market. Endocardial LAA devices are preferred due to their lower complication rates, shorter hospital stays, and fewer 30-day readmissions. Numerous clinical studies have demonstrated that endocardial LAA devices are safer and more effective in managing stroke and reducing bleeding compared to other options.

Moreover, the devices offer various benefits including ease of use and a robust product pipeline. Notable devices like the Watchman, which has received U.S. approval, and seven other devices with CE marks in Europe, contribute to this growth. These devices are currently undergoing clinical trials, further expanding the market.

Request Customizationto receive a tailored report.

End-User Insights

The market is bifurcated into hospitals, ambulatory surgery centers, and others. The hospital segment is estimated to own the market. Market players focus on promoting their products in hospitals through financial incentives and marketing strategies. For instance, Boston Scientific collaborated with MedAxiom and TogetherMD to offer value-based solutions in hospitals aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems..Hospitals adopt advanced medical technologies and have certified medical professionals, making them the preferred choice for LAAC procedures. For instance, Glenfield Hospital was one of the first to implant Boston Scientific’s WATCHMAN FLX LAAC device following its CE mark approval.

Thereby, the growth of the segment is driven by the increasing preference for LAA surgeries, the adoption of advanced LAAC devices, and the availability of cutting-edge medical technologies and skilled staff in hospitals.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global left atrial appendage closure devices market shareholder and is expected to expand substantially during the forecast period. North America stands as a prominent region in the global market, characterized by the high prevalence of atrial fibrillation, well-established healthcare facilities and advanced medical technology, supporting the widespread adoption of innovative medical devices.

The United States left atrial appendage closure device industry is leading in terms of market share. The presence of major companies involved in the production of the LAA closure devices such as Boston Scientific and Abbott, have a strong presence in the country, contributing to the region's market leadership. Additionally, in the U.S., the Centers for Medicare & Medicaid Services (CMS) provide coverage for LAA closure devices, making them more accessible to patients and encouraging their use.

The Canadian market for left atrial appendage closure device is poised to grow due to technological innovations in the field of structural heart diseases by different players in the market in the ocuntry. For instance, the approval of the Amplatzer Steerable Delivery Sheath and Amulet LAA Occluder provides Canadian physicians with an advanced and innovative solution for managing stroke risk in patients with AF. This approval expands the treatment options available for patients who are unable to take long-term blood thinners, thereby, expanding the market growth.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Left Atrial Appendage Closure Devices Market Trends

Europe region is a pivotal market for left atrial appendage closure devices. Atrial fibrillation (AF) is the most common heart rhythm disorder and is responsible for a significant proportion of healthcare spending in European countries. As per the European Society of Cardiology, the estimated number of people suffering from AF are 7.6 million in 2016 and will increase upto 14.4 million by 2060, representing an 89% increase, resulting, in the rising demand for adequate treatment and devices such as left atrial appendage closure devices.

Germany left atrial appendage closure (LAAC) device market plays a significant role in influencing the dynamics of the Europe LAAC device market. This is evident from the substantial increase in the total number of LAAC procedures in Germany from 2016 to 2020, particularly with a notable rise in the utilization of endocardial occlusion devices. The increase in the number of centers offering endocardial LAA occlusion also contributed to this growth, driven by factors such as the aging population, increased awareness about LAAC, and advancements in technology.

France is also leading in left atrial appendage closure devices market due to the prevalence of atrial fibrillation (AF) in France, with over 1 million people suffering from the condition and over 77,000 new diagnoses annually as per the European Medical Journal. Such rising numbers are indicating the need for effective treatment options such as left atrial appendage closure (LAAC) devices. These devices have the potential to improve patient outcomes, reduce healthcare costs, and alleviate the burden on the healthcare system.

Thus, the factors above are estimated to boost the Europe left atrial appendage closure device market growth.

List of Key and Emerging Players in Left Atrial Appendage Closure Devices Market